3 FTSE 100 stocks I’d buy for growth in 2022

FTSE 100 stocks can be fast growers too. Roland Head looks at three heavyweights with big growth forecasts, including an Asian growth stock and a pharma name.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Key points

  • These FTSE 100 stocks are each expected to deliver earnings growth of 17% or more over the coming year
  • They provide access to exciting growth markets including Asian consumers and cutting-edge medicine
  • All three of these stocks appear reasonably priced

Today I want to talk about three FTSE 100 stocks with the potential to deliver sparkling growth in 2022. They’re reasonably priced, too, in my view, which is why I’d consider adding them to my portfolio today.

Healthcare hero

My first pick is pharmaceutical giant AstraZeneca (LSE: AZN). CEO Pascal Soriot has spent the last nine years rebuilding the company’s pipeline of new products.

This patient approach was needed after previous management left the cupboard bare. But AstraZeneca’s heavy investment in research and development is starting to deliver serious results. Sales rose by 32% during the first nine months of 2021, while underlying earnings climbed 22%. Full-year forecasts suggest 2021 earnings growth of 27%.

There’s always some risk that new medicines won’t achieve the blockbuster success that’s hoped for. But City brokers expect AstraZeneca’s earnings to rise by further 31% in 2022. These forecasts price the stock on 18 times 2022 forecast earnings, with a 2.4% dividend yield.

That’s cheap enough for me to consider the stock as a potential buy for my portfolio.

FTSE 100 stock, pure Asian growth

Over the last three years, FTSE 100 stock Prudential (LSE: PRU) has spun off its UK and US businesses and transformed itself into a pure-play insurer that’s focused on fast-growing consumer markets in Asia and Africa.

One downside of this strategic shift is that the dividend has been slashed and now yields just 1%. There’s also no guarantee that past rates of growth will be maintained.

However, I think the Pru’s results so far look promising. New business sales in Asia and Africa rose by 17% to $2,083m during the first half of last year. Adjusted operating profit for the same period climbed 19% to $1,571m.

Analysts expect the after-tax profit from Prudential’s Asia and Africa businesses to rise by 31% for 2021. In 2022, profits are expected to climb a further 17%. That leaves Prudential stock trading on just 15 times 2022 forecast earnings, which looks modest to me. I’d be happy to consider buying this share at current levels.

Packaging growth play

Internet shoppers caused demand for packaging to boom last year. FTSE 100 cardboard box specialist DS Smith (LSE: SMDS) saw sales rise by 22% to £3,362m during the six months to 31 October. Adjusted earnings per share were 33% higher, at 13.7p.

Broker forecasts for the full year to 30 April suggest this momentum will continue, with earnings of 16.2p per share for the second half of the year (which included Christmas). Of course, these numbers rely on continuing strong demand. Inflation is also a potential risk — the costs of paper and energy have risen sharply.

However, CEO Miles Roberts says that Smith’s has been able to increase its prices. This has offset most of the big cost increases and should protect the group’s profits. Brokers also remain bullish. The City expects to see earnings rise by a further 19% in the 2022-23 financial year.

I think DS Smith looks reasonably priced and should be positioned well for growth. I also like the group’s focus on recycling and the circular economy. I’d be buying DS Smith today if I didn’t already hold a sizeable chunk in my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns DS Smith. The Motley Fool UK has recommended DS Smith, and Prudential. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »